Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 30:5:1598726.
doi: 10.3389/fruro.2025.1598726. eCollection 2025.

High-dose-rate brachytherapy lowers travel burden for men with localized prostate cancer compared with external beam radiation

Catherine Liu  1 , Hongmei Yang  2 , Kevin Bylund  3 , Michael Cummings  3 , Hong Zhang  3
Affiliations

High-dose-rate brachytherapy lowers travel burden for men with localized prostate cancer compared with external beam radiation

Catherine Liu et al. Front Urol. .

Abstract

Objective: There are many treatment options for localized prostate cancer, including external beam radiation therapy (EBRT), stereotactic body radiation therapy (SBRT), and prostate brachytherapy (BT). This study aimed to compare the travel burdens of high-dose-rate brachytherapy (HDR-BT) at our BT center and EBRT or SBRT if administered close to home.

Materials and methods: This single-institution retrospective cohort study included 69 patients who had HDR-BT monotherapy for their prostate cancer from August 2017 to December 2022. The travel burden for HDR-BT monotherapy was estimated using Google Maps by measuring the distance from each patient's home address to our BT center. The total travel burden was calculated by multiplying the number of treatment fractions required for each modality by the roundtrip travel distance between the home and the treatment facility. Treatment toxicity was evaluated using the Expanded Prostate Index Composite for Clinical Practice (EPIC-CP) questionnaire.

Results: The median age of the 69 patients was 67 years. The mean distance from home to the BT center was 37.4 mi, while the mean distance to the nearest radiation facility was 8.3 mi. The mean total travel distance for HDR-BT was 150 mi, while those for EBRT and SBRT were 463 and 83 mi, respectively. HDR-BT resulted in a mean travel burden reduction of 313 mi compared with EBRT. The EPIC-CP scores indicated minimal posttreatment toxicity, with most patients reporting stable or improved symptoms.

Conclusion: HDR-BT monotherapy significantly reduces the travel burden compared with EBRT for localized prostate cancer, with minimal treatment-associated toxicity. Increasing the availability of BT centers could further alleviate the travel burden. Alternatively, providing transportation support could improve access to care.

Keywords: access to care; external beam radiation therapy; high-dose-rate brachytherapy; patient travel burden; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
(A) Distance in miles between a patient’s home and the facilities offering external beam radiation therapy (EBRT)/stereotactic body radiation therapy (SBRT) or high-dose-rate brachytherapy (HDR-BT). (B) Total travel burden as defined by the total miles traveled over the entire duration of treatment for EBRT, SBRT, and HDR-BT. (C) Difference in the total travel burden for each patient as calculated by the total EBRT travel burden − total HDR-BT travel burden. (D) Difference in the total travel burden for each patient as calculated by the total SBRT travel burden − total HDR-BT travel burden. Horizontal bars represent average values.
Figure 2
Figure 2
(A–C) Average Expanded Prostate Index Composite for Clinical Practice (EPIC-CP) genitourinary (A), gastrointestinal (B), and sexual (C) scores over time.
Figure 3
Figure 3
Kaplan–Meier overall survival (OS) (A) and disease-free survival (DFS) (B) curves.
See this image and copyright information in PMC

References

    1. Society AC. Key statistics for prostate cancer (2024). Available online at: https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics... (Accessed June 23, 2025).
    1. Coughlin SS. A review of social determinants of prostate cancer risk, stage, and survival. Prostate Int. (2020) 8:49–54. doi: 10.1016/j.prnil.2019.08.001 - DOI - PMC - PubMed
    1. Turner M, Carriere R, Fielding S, Ramsay G, Samuel L, Maclaren A, et al. The impact of travel time to cancer treatment centre on post-diagnosis care and mortality among cancer patients in Scotland. Health Place. (2023) 84:1–11. doi: 10.1016/j.healthplace.2023.103139 - DOI - PubMed
    1. Aggarwal A, Han L, Tree A, Lewis D, Roques T, Sangar V, et al. Impact of centralization of prostate cancer services on the choice of radical treatment. BJU Int. (2023) 131:53–62. doi: 10.1111/bju.15830 - DOI - PMC - PubMed
    1. Slevin F, Zattoni F, Checcucci E, Cumberbatch MGK, Nacchia A, Cornford P, et al. A systematic review of the efficacy and toxicity of brachytherapy boost combined with external beam radiotherapy for nonmetastatic prostate cancer. Eur Urol Oncol. (2024) 7:677–96. doi: 10.1016/j.euo.2023.11.018 - DOI - PubMed

LinkOut - more resources